Comparison of drug-eluting stent with bare metal stent for distal de novo unprotected left main coronary artery stenosis: A propensity score-matched cohort study

Circulation Journal

Volumn 75, Issue 2, 2011, Pages 290-298

  Hsueh, Shu Kai ^a   Wu, Chiung Jen ^a   Fang, Hsiu Yu ^a   Hsieh, Yuan Kai ^a   Fang, Chih Yuan ^a   Chen, Chien Jen ^a   Chen, Shyh Ming ^a   Yang, Cheng Hsu ^a   Yip, Hon Kan ^a   Chen, Mien Cheng ^a   Fu, Morgan ^a   Cheng, Cheng I ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Bare metal stent; Drug eluting stent; Left main coronary artery

Indexed keywords

AGED; ARTICLE; BARE METAL STENT; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; FEMALE; HEART FAILURE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROPENSITY SCORE; RISK FACTOR; UNPROTECTED LEFT MAIN CORONARY ARTERY STENOSIS;

AGED; ANGIOPLASTY, BALLOON, CORONARY; COHORT STUDIES; CORONARY RESTENOSIS; CORONARY STENOSIS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HEART FAILURE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; SELECTION BIAS; SEVERITY OF ILLNESS INDEX; STENTS; TREATMENT OUTCOME;

EID: 79251586276     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0468     Document Type: Article

References (43)

1. Kandzari DE, Colombo A, Park SJ, Tommaso CL, Ellis SG, Guzman LA, et al. Revascularization for unprotected left main disease: Evolution of the evidence basis to redefine treatment standards. J Am Coll Cardiol 2009; 54: 1576-1588.
2. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (updating the 2005 Guideline and 2007 Focused Update): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009; 120: 2271-2306.
3. Cheng CI, Hsueh SK, Lee FY, Wu CJ, Fang CY, Sheu JJ, et al. Clinical presentation and prognostic factors of patients with acute ST-segment elevation myocardial infarction following emergent revascularization for left main coronary artery obstruction. Circ J 2008; 72: 1598-1604.
4. Cheng CI, Lee FY, Chang JP, Hsueh SK, Hsieh YK, Fang CY, et al. Long-term outcomes of intervention for unprotected left main coronary artery stenosis: Coronary stenting vs coronary artery bypass grafting. Circ J 2009; 73: 705-712.
5. Kataoka Y, Yasuda S, Morii I, Kawamura A, Miyazaki S. Improved long-term prognosis of elderly women in the era of sirolimus-eluting stents. Circ J 2009; 73: 1219-1227.
6. Park KW, Kang SH, Chung WY, Lee HY, Park JS, Kang HJ, et al. 'Real world' comparison of drug-eluting stents vs bare metal stents in the treatment of unselected patients with acute ST-segment elevation myocardial infarction. Circ J 2010; 74: 1111-1120.
7. Buszman PE, Buszman PP, Kiesz RS, Bochenek A, Trela B, Konkolewska M, et al. Early and long-term results of unprotected left main coronary artery stenting: The LE MANS (Left Main Coronary Artery Stenting) registry. J Am Coll Cardiol 2009; 54: 1500-1511.
8. Chieffo A, Park SJ, Meliga E, Sheiban I, Lee MS, Latib A, et al. Late and very late stent thrombosis following drug-eluting stent implantation in unprotected left main coronary artery: A multicentre registry. Eur Heart J 2008; 29: 2108-2115.
9. Meliga E, Garcia-Garcia HM, Valgimigli M, Chieffo A, Biondi-Zoccai G, Maree AO, et al. Longest available clinical outcomes after drug-eluting stent implantation for unprotected left main coronary artery disease: The DELFT (Drug Eluting stent for LeFT main) Registry. J Am Coll Cardiol 2008; 51: 2212-2219.
10. Valgimigli M, van Mieghem CA, Ong AT, Aoki J, Granillo GA, McFadden EP, et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin- Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 2005; 111: 1383-1389.
11. Seung KB, Park DW, Kim YH, Lee SW, Lee CW, Hong MK, et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med 2008; 358: 1781-1792.
12. Taggart DP, Kaul S, Boden WE, Ferguson TB Jr, Guyton RA, Mack MJ, et al. Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. J Am Coll Cardiol 2008; 51: 885-892.
13. Chieffo A, Morici N, Maisano F, Bonizzoni E, Cosgrave J, Montorfano M, et al. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: A single-center experience. Circulation 2006; 113: 2542-2547.
14. Chen SL, Ye F, Zhang JJ, Liu ZZ, Lin S, Zhu ZS, et al. Distal left main coronary bifurcation lesions predict worse outcome in patients undergoing percutaneous implantation of drug-eluting stents: Results from the Drug-Eluting Stent for the Treatment of Left Main Disease (DISTAL) Study. Cardiology 2009; 113: 264-273.
15. Han Y, Wang S, Jing Q, Li Y, Liu H, Ma Y, et al. Comparison of long-term efficacy of the paclitaxel-eluting stent versus the baremetal stent for treatment of unprotected left main coronary artery disease. Am J Cardiol 2009; 103: 194-198.
16. Kim YH, Park DW, Lee SW, Yun SC, Lee CW, Hong MK, et al. Long-term safety and effectiveness of unprotected left main coronary stenting with drug-eluting stents compared with bare-metal stents. Circulation 2009; 120: 400-407.
17. Palmerini T, Marzocchi A, Tamburino C, Sheiban I, Margheri M, Vecchi G, et al. Two-year clinical outcome with drug-eluting stents versus bare-metal stents in a real-world registry of unprotected left main coronary artery stenosis from the Italian Society of Invasive Cardiology. Am J Cardiol 2008; 102: 1463-1468.
18. Tamburino C, Di Salvo ME, Capodanno D, Palmerini T, Sheiban I, Margheri M, et al. Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes. Am J Cardiol 2009; 103: 187-193.
19. Erglis A, Narbute I, Kumsars I, Jegere S, Mintale I, Zakke I, et al. A randomized comparison of paclitaxel-eluting stents versus baremetal stents for treatment of unprotected left main coronary artery stenosis. J Am Coll Cardiol 2007; 50: 491-497.
20. Valgimigli M, Malagutti P, Rodriguez Granillo GA, Tsuchida K, Garcia-Garcia HM, van Mieghem CA, et al. Single-vessel versus bifurcation stenting for the treatment of distal left main coronary artery disease in the drug-eluting stenting era: Clinical and angiographic insights into the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registries. Am Heart J 2006; 152: 896-902.
21. Birnie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS. Association between antibodies to heat shock protein 65 and coronary atherosclerosis: Possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998; 19: 387-394.
22. Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: An angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1: 219-227.
23. Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16: 9-13.
24. Iakovou I, Ge L, Colombo A. Contemporary stent treatment of coronary bifurcations. J Am Coll Cardiol 2005; 46: 1446-1455.
25. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996; 335: 217-225.
26. Thygesen K, Alpert JS, White HD, Jaffe AS, Apple FS, Galvani M, et al. Universal definition of myocardial infarction. Circulation 2007; 116: 2634-2653.
27. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
28. Chieffo A, Stankovic G, Bonizzoni E, Tsagalou E, Iakovou I, Montorfano M, et al. Early and mid-term results of drug-eluting stent implantation in unprotected left main. Circulation 2005; 111: 791-795.
29. Park SJ, Kim YH, Lee BK, Lee SW, Lee CW, Hong MK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: Comparison with bare metal stent implantation. J Am Coll Cardiol 2005; 45: 351-356.
30. Sonoda S, Morino Y, Ako J, Terashima M, Hassan AH, Bonneau HN, et al. Impact of final stent dimensions on long-term results following sirolimus-eluting stent implantation: Serial intravascular ultrasound analysis from the sirius trial. J Am Coll Cardiol 2004; 43: 1959-1963.
31. Hong MK, Mintz GS, Pichard AD, Satler LF, Kent KM, Popma JJ, et al. Intravascular ultrasound predictors of target lesion revascularization after stenting of protected left main coronary artery stenoses. Am J Cardiol 1999; 83: 175-179.
32. Applegate RJ, Sacrinty MT, Kutcher MA, Santos RM, Gandhi SK, Little WC. Effect of length and diameter of drug-eluting stents versus bare-metal stents on late outcomes. Circ Cardiovasc Interv 2009; 2: 35-42.
33. Mauri L, O'Malley AJ, Cutlip DE, Ho KK, Popma JJ, Chauhan MS, et al. Effects of stent length and lesion length on coronary restenosis. Am J Cardiol 2004; 93: 1340-1346, A5.
34. Valgimigli M, Malagutti P, Rodriguez-Granillo GA, Garcia-Garcia HM, Polad J, Tsuchida K, et al. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: An integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (TSEARCH) registries. J Am Coll Cardiol 2006; 47: 1530-1537.
35. Sheiban I, Sillano D, Biondi-Zoccai G, Chieffo A, Colombo A, Vecchio S, et al. Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents 70 restenotic cases from a cohort of 718 patients: FAILS (Failure in Left Main Study). J Am Coll Cardiol 2009; 54: 1131-1136.
36. Lefevre T, Louvard Y, Morice MC, Dumas P, Loubeyre C, Benslimane A, et al. Stenting of bifurcation lesions: Classification, treatments, and results. Catheter Cardiovasc Interv 2000; 49: 274-283.
37. Holper EM, Blair J, Selzer F, Detre KM, Jacobs AK, Williams DO, et al. The impact of ejection fraction on outcomes after percutaneous coronary intervention in patients with congestive heart failure: An analysis of the National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry and Dynamic Registry. Am Heart J 2006; 151: 69-75.
38. Bollati M, Gerasimou A, Sillano D, Biondi-Zoccai G, Garrone P, Moretti C, et al. Results of percutaneous drug-eluting stent implantation for unprotected left main coronary disease according to left ventricular systolic function. Catheter Cardiovasc Interv 2010; 75: 586-593.
39. Dzau V, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: A workshop consensus statement. Am Heart J 1991; 121: 1244-1263.
40. Engstrom G, Hedblad B, Tyden P, Lindgarde F. Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: A population-based cohort study. Atherosclerosis 2009; 202: 617-622.
41. Momiyama Y, Kawaguchi A, Kajiwara I, Ohmori R, Okada K, Saito I, et al. Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: The Japan NCVC-Collaborative Inflammation Cohort (JNIC) Study. Atherosclerosis 2009; 207: 272-276.
42. Zimmermann O, Bienek-Ziolkowski M, Wolf B, Vetter M, Baur R, Mailander V, et al. Myocardial inflammation and non-ischaemic heart failure: Is there a role for C-reactive protein? Basic Res Cardiol 2009; 104: 591-599.
43. Palmerini T, Marzocchi A, Marrozzini C, Ortolani P, Saia F, Bacchi-Reggiani L, et al. Preprocedural levels of C-reactive protein and leukocyte counts predict 9-month mortality after coronary angioplasty for the treatment of unprotected left main coronary artery stenosis. Circulation 2005; 112: 2332-2338.